ArticleScientific reports2025
Ustekinumab may have therapeutic effects on autoimmune thyroid disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-12 and IL-23 play crucial roles in initiating and maintaining autoimmunity, which is implicated in autoimmune thyroid disease (AITD). This study evaluated the effect of ustekinumab, a biologic agent targeting IL-12/23, on AITD in patients with inflammatory bowel disease (IBD). A total of 203 IBD patients and 58 age- and sex-matched healthy controls underwent comprehensive thyroid examinations including biochemical tests and sonography. Among the IBD patients, 127 received biologic therapy and 76 did not; 91 were treated with infliximab, 26 with adalimumab, and 10 with ustekinumab. Compared with healthy controls, patients with IBD exhibited impaired thyroid structure and a higher incidence of AITD. The incidence of AITD was lower and thyroid structure was better preserved in IBD patients receiving biologic therapy than in those not receiving it. When thyroid findings were analyzed by biologic type, ustekinumab-treated patients had the lowest AITD incidence, lower anti-thyroid peroxidase levels, and more favorable sonographic features compared with adalimumab and infliximab groups. These findings suggest that ustekinumab may have a protective or therapeutic effect on the thyroid gland and may be a potential treatment option in patients with AITD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.